These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32344070)

  • 1. Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19.
    Peterson D; Damsky W; King B
    J Am Acad Dermatol; 2020 Jul; 83(1):e67-e68. PubMed ID: 32344070
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: Potential role of Janus kinase inhibitors in COVID-19.
    Napolitano M; Fabbrocini G; Patruno C
    J Am Acad Dermatol; 2020 Jul; 83(1):e65. PubMed ID: 32339701
    [No Abstract]   [Full Text] [Related]  

  • 3. JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk.
    Mehta P; Ciurtin C; Scully M; Levi M; Chambers RC
    Eur Respir J; 2020 Sep; 56(3):. PubMed ID: 32631841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology.
    Jessica Chang TY; Pope JE
    Immunotherapy; 2020 Oct; 12(15):1115-1119. PubMed ID: 32640861
    [No Abstract]   [Full Text] [Related]  

  • 5. Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?
    Raschi E; Caraceni P; Poluzzi E; De Ponti F
    Expert Opin Drug Saf; 2020 Oct; 19(10):1367-1369. PubMed ID: 32840116
    [No Abstract]   [Full Text] [Related]  

  • 6. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].
    Hasselbalch HC; Poulsen A; Skov V; Kjær L; Nielsen CH; Poulsen TD
    Ugeskr Laeger; 2020 Jun; 182(25):. PubMed ID: 32584762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In reply-The "Perfect Cytokine Storm" of COVID-19.
    Vijayvargiya P; Esquer Garrigos Z; Castillo Almeida NE; Gurram PR; Stevens RW; Razonable RR
    Mayo Clin Proc; 2020 Sep; 95(9):2037-2038. PubMed ID: 32861344
    [No Abstract]   [Full Text] [Related]  

  • 8. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.
    Gozzetti A; Capochiani E; Bocchia M
    Leukemia; 2020 Oct; 34(10):2815-2816. PubMed ID: 32879427
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.
    Bhaskar S; Sinha A; Banach M; Mittoo S; Weissert R; Kass JS; Rajagopal S; Pai AR; Kutty S
    Front Immunol; 2020; 11():1648. PubMed ID: 32754159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics, spondylitis and COVID-19.
    Rosenbaum JT; Hamilton H; Choi D; Weisman MH; Reveille JD; Winthrop KL
    Ann Rheum Dis; 2020 Dec; 79(12):1663-1665. PubMed ID: 32522741
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatments for COVID-19: emerging drugs against the coronavirus - reply.
    Potì F
    Acta Biomed; 2020 Jun; 91(3):ahead of print. PubMed ID: 32921741
    [No Abstract]   [Full Text] [Related]  

  • 12. Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
    Haberman R; Axelrad J; Chen A; Castillo R; Yan D; Izmirly P; Neimann A; Adhikari S; Hudesman D; Scher JU
    N Engl J Med; 2020 Jul; 383(1):85-88. PubMed ID: 32348641
    [No Abstract]   [Full Text] [Related]  

  • 13. The "Perfect Cytokine Storm" of COVID-19.
    Testori A
    Mayo Clin Proc; 2020 Sep; 95(9):2036-2037. PubMed ID: 32861343
    [No Abstract]   [Full Text] [Related]  

  • 14. COVID-19 in Spain: a predictable storm?
    The Lancet Public Health
    Lancet Public Health; 2020 Nov; 5(11):e568. PubMed ID: 33075295
    [No Abstract]   [Full Text] [Related]  

  • 15. Reply Letter - COVID-19 (Novel Coronavirus 2019) - Recent trends.
    Kannan S; Shaik Syed Ali Pakeer P; Sheeza Ali A; Hemalatha K
    Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6482-6483. PubMed ID: 32633333
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to "Coronavirus Disease 19 (COVID-19): Implications for Clinical Dental Care".
    Ather A; Patel B; Ruparel NB; Diogenes A; Hargreaves KM
    J Endod; 2020 Sep; 46(9):1342. PubMed ID: 32810475
    [No Abstract]   [Full Text] [Related]  

  • 17. In Reply to the Letter to the Editor Regarding "Neurological Impact of Coronavirus Disease (COVID-19): Practical Considerations for the Neuroscience Community".
    Scullen T; Mathkour M; Keen JR
    World Neurosurg; 2020 Oct; 142():535-536. PubMed ID: 32585382
    [No Abstract]   [Full Text] [Related]  

  • 18. REPLY TO: Interleukin-17: a potential therapeutic target in COVID-19.
    Piaserico S; Meneguzzo A; Messina F
    J Infect; 2020 Sep; 81(3):e37-e38. PubMed ID: 32610110
    [No Abstract]   [Full Text] [Related]  

  • 19. Authors' Reply to: Errors in Tracing Coronavirus SARS-CoV-2 Transmission Using a Maximum Likelihood Tree. Comment on "A Snapshot of SARS-CoV-2 Genome Availability up to April 2020 and its Implications: Data Analysis".
    Mavian C; Marini S; Prosperi M; Salemi M
    JMIR Public Health Surveill; 2020 Nov; 6(4):e24661. PubMed ID: 33174844
    [No Abstract]   [Full Text] [Related]  

  • 20. Histamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19.
    Eldanasory OA; Eljaaly K; Memish ZA; Al-Tawfiq JA
    Travel Med Infect Dis; 2020; 37():101874. PubMed ID: 32891724
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.